Disclaimer first up: my opinions only, not advice, please do your own research.
This thread is intended to have a bit of fun and a stab at what some numbers could just possibly look like for Year Ended 30 June 2020 (FY20) and FY21.
Have been conservative in parts, but slightly less so in others. Lots of assumptions basically.
Have applied/assumed very little B2B wins at this time, and can accept that below could be rubbish because of the very high likelihood of distribution deals new and existing occurring in the near term!
FY20 revenues of 21m; 2H20 revs at 19.4m.
FY21 revenues at 40.6m; PE at 29 at a SP of $2.25
For the E in PE, I’ve used after tax at 28pc ax (I think it’s 28pc in NZ).
Overall I think there is certainly plenty of room to run, due to the high likelihood of deals in the near term getting traction (new and existing) and strong trading conditions, including the impact of (recent) free press and marketing, on a global stage I might add!
Open to thoughts and comments, although I kindly request it’s kept respectful.
- Forums
- ASX - By Stock
- ZNO
- A rudimentary valuation stab
A rudimentary valuation stab
-
- There are more pages in this discussion • 76 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ZNO (ASX) to my watchlist
(20min delay)
|
|||||
Last
2.5¢ |
Change
-0.002(7.41%) |
Mkt cap ! $8.885M |
Open | High | Low | Value | Volume |
2.5¢ | 2.5¢ | 2.5¢ | $5.49K | 219.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 340519 | 2.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.7¢ | 41763 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 340519 | 0.025 |
2 | 42208 | 0.024 |
1 | 300000 | 0.023 |
2 | 138322 | 0.022 |
1 | 23840 | 0.021 |
Price($) | Vol. | No. |
---|---|---|
0.027 | 41763 | 1 |
0.028 | 297867 | 1 |
0.029 | 252612 | 1 |
0.030 | 703000 | 3 |
0.032 | 258906 | 2 |
Last trade - 11.50am 13/11/2024 (20 minute delay) ? |
Featured News
ZNO (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online